NVIDIA To $240? Here Are 5 Other Price Target Changes For Tuesday

Raymond James cut the price target on NVIDIA Corporation (NASDAQ: NVDA) from $250 to $240. Raymond James analyst Melissa Fairbanks maintained the stock with a Strong Buy. NVIDIA shares fell 2.8% to $172.92 in pre-market trading.
  • Raymond James cut the price target on NVIDIA Corporation (NASDAQ:NVDA) from $250 to $240. Raymond James analyst Melissa Fairbanks maintained the stock with a Strong Buy. NVIDIA shares fell 2.8% to $172.92 in pre-market trading.
  • Piper Sandler boosted monday.com Ltd. (NASDAQ:MNDY) price target from $150 to $180. However, Piper Sandler analyst Brent Bracelin maintained an Overweight rating on the stock. monday.com shares fell 1.8% to $147.77 in pre-market trading.
  • Wells Fargo cut Tandem Diabetes Care, Inc. (NASDAQ:TNDM) price target from $82 to $49. Wells Fargo analyst Larry Biegelsen also downgraded the stock from Overweight to Underweight. Tandem Diabetes Care shares fell 2% to $58.90 in pre-market trading.
  • BMO Capital raised Brunswick Corporation (NYSE:BC) price target from $90 to $110. BMO Capital analyst Gerrick Johnson upgraded the stock from Market Perform to Outperform. Brunswick shares rose 1.4% to $81.08 in pre-market trading.
  • HC Wainwright & Co. raised ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) price target from $20 to $25. However, HC Wainwright & Co. analyst Andrew Fein maintained a Buy rating on the stock. ACADIA Pharmaceuticals rose 1.1% to close at $16.62 on Monday.
  • Chardan Capital cut CRISPR Therapeutics AG (NASDAQ:CRSP) price target from $164 to $154. However, Chardan Capital analyst Geulah Livshits maintained the stock with a Buy. CRISPR Therapeutics shares dropped 2.6% to $79.30 in pre-market trading.

Check out this: Why Is BIMI International Medical Higher By Around 70%: Here Are 38 Stocks Moving Premarket

Total
0
Shares
Related Posts
Read More

Genetic Technologies Announced Partnership With Siles Health to Bring GeneType Risk Test to 9 Clinics

Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, "Company", "GTG"), a global leader in genomics-based tests in health, wellness and serious disease is delighted to announce that we are partnering with Melbourne based Siles Health, a leading Obstetrics and Gynaecology practice, to implement geneType Multi-Risk Test as part of their commitment to remain at the forefront of contemporary personal

GENE